BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 6754062)

  • 1. Vincristine, doxorubicin, and cyclophosphamide versus low-dose intravenous cyclophosphamide, methotrexate, and 5-fluorouracil in advanced breast cancer: a randomized trial of the Piedmont Oncology Association.
    Muss HB; Richards F; Jackson DV; Cooper MR; White DR; Stuart JJ; Ramseur W; Christian RM; Wells HB; Pope E; Spurr CL
    Cancer; 1982 Dec; 50(11):2269-74. PubMed ID: 6754062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new six-drug antiblastic regimen (R 14) at low doses (micropolychemotherapy) compared to CMF in the treatment of metastatic breast cancer: phase III study.
    Pannuti F; Iafelice G; Martoni A; Fruet F; Angelelli B; Casadei M
    Chemioterapia; 1984 Aug; 3(4):216-9. PubMed ID: 6398121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose cyclophosphamide and 5-fluorouracil versus vincristine, doxorubicin, and cyclophosphamide in advanced carcinoma of the breast. A phase III study of the Piedmont Oncology Association (POA).
    Zekan PJ; Muss HB; Capizzi RL; Cooper MR; Harding RW; Hopkins JO; Jackson DV; Ramseur WL; Richards F; Spurr CL
    Cancer; 1984 Dec; 54(11):2338-43. PubMed ID: 6388802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low dose chemotherapy of metastatic breast cancer with cyclophosphamide, adriamycin, methotrexate, 5-fluorouracil (CAMF) versus sequential cyclophosphamide, methotrexate, 5-fluorouracil (CMF) and adriamycin.
    Creech RH; Catalano RB; Harris DT; Engstrom PF; Grotzinger PJ
    Cancer; 1979 Jan; 43(1):51-9. PubMed ID: 367574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adriamycin plus vincristine compared to and combined with cyclophosphamide, methotrexate, and 5-fluorouracil for advanced breast cancer.
    De Lena M; Brambilla C; Morabito A; Bonadonna G
    Cancer; 1975 Apr; 35(4):1108-15. PubMed ID: 1116104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MMM (mitomycin/mitoxantrone/methotrexate): an effective new regimen in the treatment of metastatic breast cancer.
    Smith IE; Powles TJ
    Oncology; 1993 Apr; 50 Suppl 1():9-15. PubMed ID: 8483562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy of advanced breast cancer: a randomized trial of vincristine, Adriamycin, and cyclophosphamide (VAC) versus cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP).
    Carmo-Pereira J; Costa FO; Henriques E
    Cancer; 1981 Oct; 48(7):1517-21. PubMed ID: 7026020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) versus intravenous cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in first-line chemotherapy for patients with metastatic breast carcinoma: a randomized phase II trial.
    Hainsworth JD; Jolivet J; Birch R; Hopkins LG; Greco FA
    Cancer; 1997 Feb; 79(4):740-8. PubMed ID: 9024712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of cyclophosphamide, adriamycin, 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednisone (CMFVP) in patients with metastatic breast cancer: a Southeastern Cancer Study Group project.
    Smalley RV; Carpenter J; Bartolucci A; Vogel C; Krauss S
    Cancer; 1977 Aug; 40(2):625-32. PubMed ID: 329975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized study of combination chemotherapy (VAC-FMC) with or without immunostimulation by Corynebacterium parvum in metastatic breast cancer.
    Fritze D; Becher R; Massner B; Kaufmann M; Bruntsch U; Gallmeier WM; Mayr AC; Drings P; Abel U; Edler L; Jungi WF; Queisser W; Senn HJ
    Klin Wochenschr; 1982 Jun; 60(12):593-8. PubMed ID: 7109499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination chemotherapy and adriamycin in patients with advanced breast cancer. A Southwest Oncology Group study.
    Hoogstraten B; George SL; Samal B; Rivkin SE; Costanzi JJ; Bonnet JD; Thigpen T; Braine H
    Cancer; 1976 Jul; 38(1):13-20. PubMed ID: 947510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vincristine, doxorubicin and mitomycin (VAM) in patients with advanced breast cancer previously treated with cyclophosphamide, methotrexate and fluorouracil (CMF). A clinical trial of the Piedmont Oncology Association (POA).
    Shipp SK; Muss HB; Westrick MA; Cooper MR; Jackson DV; Richards FC; White DR; Stuart JJ; Christian RM; Ramseur W
    Cancer Chemother Pharmacol; 1983; 11(2):130-3. PubMed ID: 6354509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomised trial: One cycle of anthracycline-containing adjuvant chemotherapy compared with six cycles of CMF treatment in node-positive, hormone receptor-negative breast cancer patients.
    Ploner F; Jakesz R; Hausmaninger H; Kolb R; Stierer M; Fridrik M; Steindorfer P; Gnant M; Haider K; Mlineritsch B; Tschurtschenthaler G; Steger G; Seifert M; Kubista E; Samonigg H;
    Onkologie; 2003 Apr; 26(2):115-9. PubMed ID: 12771518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant chemotherapy in operable breast cancer: cyclophosphamide, methotrexate, and fluorouracil versus chlorambucil, methotrexate, and fluorouracil--11-year results of Swiss Group for Clinical Cancer Research trial SAKK 27/82.
    Senn HJ; Maibach R; Castiglione M; Jungi WF; Cavalli F; Leyvraz S; Obrecht JP; Schildknecht O; Siegenthaler P
    J Clin Oncol; 1997 Jul; 15(7):2502-9. PubMed ID: 9215818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy.
    Bull JM; Tormey DC; Li SH; Carbone PP; Falkson G; Blom J; Perlin E; Simon R
    Cancer; 1978 May; 41(5):1649-57. PubMed ID: 348293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapy versus chemoimmunotherapy (CAF v CAFVP v CMF each +/- MER) for metastatic carcinoma of the breast: a CALGB study. Cancer and Leukemia Group B.
    Aisner J; Weinberg V; Perloff M; Weiss R; Perry M; Korzun A; Ginsberg S; Holland JF
    J Clin Oncol; 1987 Oct; 5(10):1523-33. PubMed ID: 3655855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of different neoadjuvant chemotherapy regimens on locally advanced breast cancer.
    Coskun U; Gunel N; Onuk E; Yilmaz E; Bayram O; Yamac D; Cihan A; Ucan B; Yildirim Y; Celenkoglu G; Ozkan S
    Neoplasma; 2003; 50(3):210-6. PubMed ID: 12937855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study.
    Rivkin SE; Green SJ; Lew D; Costanzi JJ; Athens JW; Osborne CK; Vaughn CB; Martino S
    Cancer; 2003 Jan; 97(1):21-9. PubMed ID: 12491501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Encouraging results with cytostatic therapy in metastasizing breast cancer (author's transl)].
    Michlmayr G; Kratzer H; Denz H; Huber H
    Wien Klin Wochenschr; 1981 Mar; 93(6):205-7. PubMed ID: 7281697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of adjuvant chemotherapy with methotrexate and fluorouracil with and without cyclophosphamide in breast cancer patients with one to three positive axillary lymph nodes.
    Shapiro CL; Gelman RS; Hayes DF; Osteen R; Obando A; Canellos GP; Frei E; Henderson IC
    J Natl Cancer Inst; 1993 May; 85(10):812-7. PubMed ID: 8487326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.